Introduction: Biomarkers for early detection of renal cell carcinoma (RCC) may help diagnose minimal residual disease in patients at risk for RCC, can guide anti-angiogenic therapy, or may help identify candidates for adjuvant treatment. In this study, we investigated whether blood levels of carbonic anhydrase 9 (CA9) correlate with RCC tumor burden and therefore disease activity. Methods: CA9 is a von Hippel-Lindau-hypoxia inducible factor target upregulated in clear cell RCC. We used an anti-CA9 antibody (M75)-based enzyme-linked immunosorbent assay test to measure CA9 levels in blood obtained before and after nephrectomy for clinically localized disease in patients with: (1) clear cell RCC, (2) papillary and chromophobe RCC or oncocytoma, or (3) benign kidney lesions, and we compared these samples to blood drawn from normal control individuals. Results: We observed a significant (p∈
CITATION STYLE
Hulick, P., Zimmer, M., Margulis, V., Skates, S., Hamel, M., Dahl, D. M., … Iliopoulos, O. (2009). Blood levels of carbonic anhydrase 9 correlate with clear cell renal cell carcinoma activity. Clinical Proteomics, 5(1), 37–45. https://doi.org/10.1007/s12014-008-9012-1
Mendeley helps you to discover research relevant for your work.